Print

Semafore Pharmaceuticals, Inc. Announces Issuance of Key U.S. Patent Covering Composition of Matter for Novel PI3K/mTOR Pathway Inhibitor  
2/22/2010 10:02:05 AM

INDIANAPOLIS--(BUSINESS WIRE)--Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
//-->